Cargando…

Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants

The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oladunni, Fatai S., Park, Jun-Gyu, Chiem, Kevin, Ye, Chengjin, Pipenbrink, Michael, Walter, Mark R., Kobie, James, Martinez-Sobrido, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837211/ https://www.ncbi.nlm.nih.gov/pubmed/33513380 http://dx.doi.org/10.1016/j.jviromet.2021.114084

Ejemplares similares

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
por: Park, Jun-Gyu, et al.
Publicado: (2021)

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
por: Piepenbrink, Michael S., et al.
Publicado: (2021)

Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome
por: Ye, Chengjin, et al.
Publicado: (2020)

Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes
por: Chiem, Kevin, et al.
Publicado: (2021)

Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus
por: Chiem, Kevin, et al.
Publicado: (2022)

Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections
por: Martinez-Sobrido, Luis, et al.
Publicado: (2023)

A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern In Vitro and In Vivo
por: Chiem, Kevin, et al.
Publicado: (2021)

Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies
por: Piepenbrink, Michael, et al.
Publicado: (2023)

A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs
por: Park, Jun-Gyu, et al.
Publicado: (2020)

Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission
por: Ye, Chengjin, et al.
Publicado: (2023)

Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses
por: Ye, Chengjin, et al.
Publicado: (2021)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Use of a Bacterial Artificial Chromosome to Generate Recombinant SARS-CoV-2 Expressing Robust Levels of Reporter Genes
por: Ye, Chengjin, et al.
Publicado: (2022)

Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus
por: Viswanathan, Thiruselvam, et al.
Publicado: (2020)

SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
por: Gorshkov, Kirill, et al.
Publicado: (2022)

Structural basis of RNA cap modification by SARS-CoV-2
por: Viswanathan, Thiruselvam, et al.
Publicado: (2020)

A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening
por: Gorshkov, Kirill, et al.
Publicado: (2021)

Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Equine Influenza Virus and Vaccines
por: Oladunni, Fatai S., et al.
Publicado: (2021)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
por: Piepenbrink, Michael S., et al.
Publicado: (2022)

Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice
por: Silvas, Jesus A., et al.
Publicado: (2021)

A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody
por: Nogales, Aitor, et al.
Publicado: (2018)

Mitigation of SARS-CoV-2 by Using Transition Metal Nanozeolites and Quaternary Ammonium Compounds as Antiviral Agents in Suspensions and Soft Fabric Materials
por: Guerrero-Arguero, Israel, et al.
Publicado: (2023)

Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
por: Streblow, Daniel N., et al.
Publicado: (2023)

Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents
por: Zarkoob, Hoda, et al.
Publicado: (2021)

Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS‐CoV‐2
por: Kim, Jeonghwan, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2
por: Park, Jun-Gyu, et al.
Publicado: (2021)

Amino Acid Residues Involved in Inhibition of Host Gene Expression by Influenza A/Brevig Mission/1/1918 PA-X
por: Chiem, Kevin, et al.
Publicado: (2021)

A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus
por: Blanco-Lobo, Pilar, et al.
Publicado: (2019)

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody
por: Khalil, Ahmed M., et al.
Publicado: (2023)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants
por: Au, Wing Ying, et al.
Publicado: (2022)

Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
por: Lorenzo, María M., et al.
Publicado: (2023)

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
por: Oladunni, Fatai S., et al.
Publicado: (2020)

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine
por: Hilimire, Thomas A., et al.
Publicado: (2020)

Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development
por: Lorenzo, María M., et al.
Publicado: (2022)

SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming
por: Wu, Chien-Ting, et al.
Publicado: (2023)

SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
por: Lu, Mijia, et al.
Publicado: (2022)

Mutant monoclonal antibodies with alterations in biological functions
por: Yelton, DE, et al.
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_ccfn2fdmagkttcga2noompet4j